249 related articles for article (PubMed ID: 24574825)
21. Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal.
Thadani U
Expert Opin Pharmacother; 2012 Dec; 13(17):2555-63. PubMed ID: 23121448
[TBL] [Abstract][Full Text] [Related]
22. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group.
Thadani U; Ezekowitz M; Fenney L; Chiang YK
Circulation; 1994 Aug; 90(2):726-34. PubMed ID: 8044941
[TBL] [Abstract][Full Text] [Related]
23. Ranolazine for stable angina pectoris.
Salazar CA; Basilio Flores JE; Veramendi Espinoza LE; Mejia Dolores JW; Rey Rodriguez DE; Loza Munárriz C
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD011747. PubMed ID: 28178363
[TBL] [Abstract][Full Text] [Related]
24. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA;
JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593
[TBL] [Abstract][Full Text] [Related]
25. Ranolazine for the management of coronary artery disease.
Cheng JW
Clin Ther; 2006 Dec; 28(12):1996-2007. PubMed ID: 17296457
[TBL] [Abstract][Full Text] [Related]
26. Novel therapeutic approaches to treating chronic angina in the setting of chronic ischemic heart disease.
Chaitman BR; Sano J
Clin Cardiol; 2007 Feb; 30(2 Suppl 1):I25-30. PubMed ID: 18373327
[TBL] [Abstract][Full Text] [Related]
27. Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris.
Ling H; Packard KA; Burns TL; Hilleman DE
Am J Cardiovasc Drugs; 2013 Dec; 13(6):407-12. PubMed ID: 23873327
[TBL] [Abstract][Full Text] [Related]
28. Ranolazine: an anti-anginal drug with further therapeutic potential.
Reffelmann T; Kloner RA
Expert Rev Cardiovasc Ther; 2010 Mar; 8(3):319-29. PubMed ID: 20222810
[TBL] [Abstract][Full Text] [Related]
29. Ranolazine in treatment of stable angina in woman with atrial fibrillation and intermittent left bundle branch block - a case report.
Yuriivna Osovska N; Vitaliivna Kuzminova N
Pol Merkur Lekarski; 2016 Dec; 41(246):287-292. PubMed ID: 28024133
[TBL] [Abstract][Full Text] [Related]
30. [New agents for the therapy of angina pectoris].
Meinertz T; Köster R
Internist (Berl); 2011 Jul; 52(7):894-6, 898-900. PubMed ID: 21713611
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of ranolazine in patients with chronic stable angina.
Kloner RA; Hines ME; Geunes-Boyer S
Postgrad Med; 2013 Nov; 125(6):43-52. PubMed ID: 24200760
[TBL] [Abstract][Full Text] [Related]
32. Ranolazine: Multifaceted Role beyond Coronary Artery Disease, a Recent Perspective.
Ghosh GC; Ghosh RK; Bandyopadhyay D; Chatterjee K; Aneja A
Heart Views; 2018; 19(3):88-98. PubMed ID: 31007857
[TBL] [Abstract][Full Text] [Related]
33. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
Melloni C; Newby LK
Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):9-16. PubMed ID: 18095903
[TBL] [Abstract][Full Text] [Related]
34. Ranolazine: a potential new treatment for chronic stable angina.
Anderson JR; Khou S; Nawarskas JJ
Heart Dis; 2001; 3(4):263-9. PubMed ID: 11975803
[TBL] [Abstract][Full Text] [Related]
35. Ranolazine: new approach for the treatment of stable angina pectoris.
Stanley WC
Expert Rev Cardiovasc Ther; 2005 Sep; 3(5):821-9. PubMed ID: 16181027
[TBL] [Abstract][Full Text] [Related]
36. The usefulness of ranolazine for the treatment of refractory chronic stable angina pectoris as determined from a systematic review of randomized controlled trials.
Banon D; Filion KB; Budlovsky T; Franck C; Eisenberg MJ
Am J Cardiol; 2014 Mar; 113(6):1075-82. PubMed ID: 24462341
[TBL] [Abstract][Full Text] [Related]
37. Ranolazine in the management of chronic stable angina.
Zerumsky K; McBride BF
Am J Health Syst Pharm; 2006 Dec; 63(23):2331-8. PubMed ID: 17106005
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of ranolazine in hypertrophic cardiomyopathy: Real-world experience in a National Referral Center.
Argirò A; Zampieri M; Dei LL; Ferrantini C; Marchi A; Tomberli A; Baldini K; Cappelli F; Favilli S; Passantino S; Zocchi C; Tassetti L; Gabriele M; Maurizi N; Marchionni N; Coppini R; Olivotto I
Int J Cardiol; 2023 Jan; 370():271-278. PubMed ID: 36228766
[TBL] [Abstract][Full Text] [Related]
39. Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination Assessment of Ranolazine In Stable Angina (CARISA) randomized trial.
Sendón JL; Lee S; Cheng ML; Ben-Yehuda O;
Eur J Prev Cardiol; 2012 Oct; 19(5):952-9. PubMed ID: 22689417
[TBL] [Abstract][Full Text] [Related]
40. A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve.
Bairey Merz CN; Handberg EM; Shufelt CL; Mehta PK; Minissian MB; Wei J; Thomson LE; Berman DS; Shaw LJ; Petersen JW; Brown GH; Anderson RD; Shuster JJ; Cook-Wiens G; Rogatko A; Pepine CJ
Eur Heart J; 2016 May; 37(19):1504-13. PubMed ID: 26614823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
